On this episode of Stock Movers:

- Canada Goose (GOOS) shares fell today on the news that Barclays was cutting the upscale parka retailer's rating to "underweight" from "equal weight", citing challenging macro pressures.

- Vaccine and biotech stocks, including Moderna (MRNA) plunged after a top regulator left the US Food and Drug Administration, casting deep uncertainty about the future of vaccines and cutting-edge gene therapies. Peter Marks, a key figure overseeing the review and approval of vaccines and other medications, resigned on Friday, citing friction with the views of new Health and Human Services Secretary and longtime vaccine critic Robert F. Kennedy Jr.

- Celsius Holdings (CELH) shares rose to hit its highest intraday level since September after Truist Securities upgraded its recommendation to buy from hold, saying the company’s Alani Nu acquisition gives it an “extremely strong position” in the women’s segment of the US energy drink category.

On this episode of Stock Movers: - Canada Goose (GOOS) shares fell today on the news that Barclays was cutting the upscale parka retailer's rating to "underweight" from "equal weight", citing challenging macro pressures.
- Vaccine and biotech stocks, including Moderna (MRNA) plunged after a top regulator left the US Food and Drug Administration, casting deep uncertainty about the future of vaccines and cutting-edge gene therapies. Peter Marks, a key figure overseeing the review and approval of vaccines and other medications, resigned on Friday, citing friction with the views of new Health and Human Services Secretary and longtime vaccine critic Robert F. Kennedy Jr.
- Celsius Holdings (CELH) shares rose to hit its highest intraday level since September after Truist Securities upgraded its recommendation to buy from hold, saying the company&rsquo;s Alani Nu acquisition gives it an &ldquo;extremely strong position&rdquo; in the women&rsquo;s segment of the US energy drink category.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Canada Goose Falls, Celsius Rises, Moderna Slides

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/40c66d73-f126-4ff9-9df4-b2b1015c0abc/transcript

Today’s biggest winners and losers in the stock market. 

On this episode of Stock Movers: 
Shares of Meta Platforms (META) gained ahead of the Wednesday close after the social media giant said it agreed to pay up to $18 billion in landmark settlements to resolve legal claims from US states that would require the company to make major changes to how it operates platforms like Facebook and Instagram. Key parts of the deal, disclosed in a court filing Wednesday, require the company to put new guardrails on its platforms, including restricting how much time youths can scroll and preventing them from switching off certain safety settings without parental consent.
Shares of Nvidia (NVDA) moved lower ahead of the company’s latest earnings report. Investors are eagerly awaiting Nvidia’s numbers for clues on what they mean to the artificial-intelligence trade and the market itself. Analysts project that revenue nearly doubled from a year ago, which would be the fastest pace in two years, according to data compiled by Bloomberg.
Shares of Revolution Medicines Inc. (RVMD) gained in the Wednesday session after the FDA approved the firm’s once-daily tablet for adults with metastatic pancreatic cancer, the first medicine to target one of the key molecular causes of the disease. The drug, which will be called Rasonque, is one of the more significant breakthroughs in pancreatic cancer in years. In a final stage trial published in May, daraxonrasib nearly doubled typical survival time for patients with an aggressive form of the disease to 13.2 months, compared with 6.7 months for patients who received chemotherapy, the current standard of care, according to the US Food and Drug Administration.

Today&rsquo;s biggest winners and losers in the stock market.&nbsp;
On this episode of Stock Movers:&nbsp;
<ul>
<li>Shares of Meta Platforms (META) gained ahead of the Wednesday close after the social media giant said it agreed to pay up to $18 billion in landmark settlements to resolve legal claims from US states that would require the company to make major changes to how it operates platforms like Facebook and Instagram. Key parts of the deal, disclosed in a court filing Wednesday, require the company to put new guardrails on its platforms, including restricting how much time youths can scroll and preventing them from switching off certain safety settings without parental consent.</li>
<li>Shares of Nvidia (NVDA) moved lower ahead of the company&rsquo;s latest earnings report. Investors are eagerly awaiting Nvidia&rsquo;s numbers for clues on what they mean to the artificial-intelligence trade and the market itself. Analysts project that revenue nearly doubled from a year ago, which would be the fastest pace in two years, according to data compiled by Bloomberg.</li>
<li>Shares of Revolution Medicines Inc. (RVMD) gained in the Wednesday session after the FDA approved the firm&rsquo;s once-daily tablet for adults with metastatic pancreatic cancer, the first medicine to target one of the key molecular causes of the disease. The drug, which will be called Rasonque, is one of the more significant breakthroughs in pancreatic cancer in years. In a final stage trial published in May, daraxonrasib nearly doubled typical survival time for patients with an aggressive form of the disease to 13.2 months, compared with 6.7 months for patients who received chemotherapy, the current standard of care, according to the US Food and Drug Administration.</li>
</ul>

Meta Gains on Settlement, Nvidia Dips Ahead of Earnings, RevMed Rallies on FDA Approval

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/94e4bcf2-12fc-47f4-9833-b4b2014141e3/transcript

Abercrombie & Fitch (ANF) shares soar. Abercrombie & Fitch shares jump as much as 30% to trade at their highest intraday level since January 2025 after the apparel retailer raised its adjusted earnings per share guidance for the full year.

-J M Smucker (SJM) raised its full-year outlook for sales and profit, buoyed by growth in its Uncrustables sandwiches and coffee. The packaged food company said it now expects adjusted earnings per share for fiscal 2027 of between $10.50 and $11.00, up from its prior estimate of $9.75 to $10.25. Smucker expects net sales to fall 1% to 2%, an improvement over its previous forecast of a decline of 3% to 4%. 

-Zoom Communications (ZM) shares fall. The software company’s second-quarter results were seen as mixed. It also gave outlooks for adjusted third-quarter earnings and operating income that were weaker than expected. 

Abercrombie &amp; Fitch (ANF) shares soar. Abercrombie &amp; Fitch shares jump as much as 30% to trade at their highest intraday level since January 2025 after the apparel retailer raised its adjusted earnings per share guidance for the full year.
-J M Smucker (SJM) raised its full-year outlook for sales and profit, buoyed by growth in its Uncrustables sandwiches and coffee. The packaged food company said it now expects adjusted earnings per share for fiscal 2027 of between $10.50 and $11.00, up from its prior estimate of $9.75 to $10.25. Smucker expects net sales to fall 1% to 2%, an improvement over its previous forecast of a decline of 3% to 4%.&nbsp;
-Zoom Communications (ZM) shares fall. The software company&rsquo;s second-quarter results were seen as mixed. It also gave outlooks for adjusted third-quarter earnings and operating income that were weaker than expected.&nbsp;

Abercrombie & Fitch Soars, J M Smucker Rises, Zoom Communications Falls as Tepid Outlook Offsets AI Monetization

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/230a8354-1fa7-46a6-9a2e-b4b200fb50aa/transcript

On this episode of Stock Movers:

-Nvidia (NVDA) drops ahead of quarterly earnings. Wall Street is anticipating Nvidia Corp.'s earnings for what they mean to artificial intelligence investors and the market itself. Nvidia is considered the best barometer for AI spending, and its earnings will help determine if hyperscalers are still accelerating or becoming more disciplined.

-Intuit (INTU) shares slump. The tax-preparation software company gave a full-year forecast for both adjusted earnings and revenue that was weaker than expected, and which added to concerns about AI-related disruption.

- J M Smucker (SJM) raised its full-year outlook for sales and profit, buoyed by growth in its Uncrustables sandwiches and coffee. The packaged food company said it now expects adjusted earnings per share for fiscal 2027 of between $10.50 and $11.00, up from its prior estimate of $9.75 to $10.25. Smucker expects net sales to fall 1% to 2%, an improvement over its previous forecast of a decline of 3% to 4%. 

On this episode of Stock Movers:
-Nvidia (NVDA) drops ahead of quarterly earnings. Wall Street is anticipating Nvidia Corp.'s earnings for what they mean to artificial intelligence investors and the market itself. Nvidia is considered the best barometer for AI spending, and its earnings will help determine if hyperscalers are still accelerating or becoming more disciplined.
-Intuit (INTU) shares slump. The tax-preparation software company gave a full-year forecast for both adjusted earnings and revenue that was weaker than expected, and which added to concerns about AI-related disruption.
- J M Smucker (SJM) raised its full-year outlook for sales and profit, buoyed by growth in its Uncrustables sandwiches and coffee. The packaged food company said it now expects adjusted earnings per share for fiscal 2027 of between $10.50 and $11.00, up from its prior estimate of $9.75 to $10.25. Smucker expects net sales to fall 1% to 2%, an improvement over its previous forecast of a decline of 3% to 4%.&nbsp;

Nvidia Drops, Intuit Slumps, J M Smucker Rises on Positive Full Year Outlook

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e229cdd1-b2ed-4765-ad56-b4b200ef3a60/transcript

Canada Goose Falls, Celsius Rises, Moderna Slides

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips